Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1110813-31-4
Formula :	C₂₄H₂₅ClFN₅O₂
M.W :	469.94
SMILES Code :	O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC)/C=C/CN4CCCCC4
Synonyms :	PF-00299804; PF-299804; PF299
MDL No. :	MFCD19443734
InChI Key :	LVXJQMNHJWSHET-AATRIKPKSA-N
Pubchem ID :	11511120

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

HUVEC	2.5 μM	6 days	inhibited EGFR phosphorylation and significantly suppressed MES-GSC EV-stimulated endothelial cell migration and aortic ring outgrowth	Nat Commun. 2024 Apr 3;15(1):2865
HEK293/pcDNA3.1 cells	0.25, 0.5, 1 μM	72 h	No significant difference in the IC50 values for MX	J Exp Clin Cancer Res. 2018 Feb 20;37(1):31
S1-MI-80 cells	0.25, 0.5, 1 μM	72 h	Potentiate the anticancer activity of ABCG2 substrate anticancer drugs (MX and topotecan)	J Exp Clin Cancer Res. 2018 Feb 20;37(1):31
H460/MX20 cells	0.25, 0.5, 1 μM	72 h	Potentiate the anticancer activity of ABCG2 substrate anticancer drugs (MX and topotecan)	J Exp Clin Cancer Res. 2018 Feb 20;37(1):31
22Rv1	2 µM	72 h	To evaluate the effect of Dacomitinib on castration-resistant prostate cancer cells. Results showed that Dacomitinib reduced cell viability by 87.6% and induced apoptosis in 22Rv1 cells.	Br J Cancer. 2019 Jul;121(3):237-248
C4-2	2 µM	72 h	To evaluate the effect of Dacomitinib on castration-resistant prostate cancer cells. Results showed that Dacomitinib inhibited cell viability by 89.8% and induced apoptosis in C4-2 cells.	Br J Cancer. 2019 Jul;121(3):237-248
LNCaP	2 µM	72 h	To evaluate the effect of Dacomitinib on hormone-sensitive prostate cancer cells. Results showed that Dacomitinib reduced cell viability by 54.4% in LNCaP cells.	Br J Cancer. 2019 Jul;121(3):237-248
GBM6 cells	500 nM	Overnight	Inhibited EGFR phosphorylation and reduced phosphorylation of downstream AKT and ERK1/2	Neoplasia. 2018 May;20(5):432-442
452.Luc2 cells	6.25-400 nM	30 min	Inhibited EGFR phosphorylation and reduced phosphorylation of downstream AKT and ERK1/2	Neoplasia. 2018 May;20(5):432-442
Daoy.Luc2 cells	6.25-400 nM	30 min	Inhibited EGFR phosphorylation and reduced phosphorylation of downstream AKT and ERK1/2	Neoplasia. 2018 May;20(5):432-442
U87vIII.Luc2 cells	0.4-4 μM	30 min	Inhibited EGFRvIII phosphorylation and reduced phosphorylation of downstream AKT and ERK1/2	Neoplasia. 2018 May;20(5):432-442
U87.Luc2 cells	0.4-4 μM	30 min	Inhibited EGFRvIII phosphorylation and reduced phosphorylation of downstream AKT and ERK1/2	Neoplasia. 2018 May;20(5):432-442
WZ4002-resistant PC9 cells	1 μM	72 h	Evaluate the growth inhibitory effect of WZ4002 on PC9 cells and their resistant clones, showing that the IC50 of resistant cells to WZ4002 was about 10-fold higher than that of parental PC9 cells	Cancer Res. 2013 Jan 15;73(2):834-43.
PC9 cells	1 μM	72 h	Evaluate the growth inhibitory effect of PF299804 on PC9 cells and their resistant clones, showing that the IC50 of resistant cells to PF299804 was more than 100-fold higher than that of parental PC9 cells	Cancer Res. 2013 Jan 15;73(2):834-43.
SBA-16 cells	2.5nM	72 h	To evaluate the anti-proliferative effect of Dacomitinib on ERBB2-mutant cell lines, showing an IC50 of 2.5nM.	Clin Cancer Res. 2019 Jan 15;25(2):641-651
SBA-6 cells	1nM	72 h	To evaluate the anti-proliferative effect of Dacomitinib on ERBB2-mutant cell lines, showing an IC50 of 1nM.	Clin Cancer Res. 2019 Jan 15;25(2):641-651

NSG mice	Glioblastoma xenograft model	Oral gavage	15 mg/kg	5 consecutive days followed by a 2-day break	Evaluated the effect of Dacomitinib alone or in combination with anti-VEGFR2 antibody on tumor growth and vascular patterns, significantly prolonged survival and disrupted vasectasia	Nat Commun. 2024 Apr 3;15(1):2865
Nude mice (BALB/c-nu/nu)	H460/MX20 cell xenograft model	Oral	5 mg/kg	Every other day for 25 days	Significantly enhanced the antitumor efficacy of topotecan in ABCG2-overexpressing H460/MX20 cell xenografts	J Exp Clin Cancer Res. 2018 Feb 20;37(1):31
Mice	U87vIII.Luc2 glioblastoma xenograft model	Oral gavage	30 mg/kg	Thrice weekly	Dacomitinib significantly extended the lifespan of mice bearing U87vIII.Luc2 glioblastoma xenografts	Neoplasia. 2018 May;20(5):432-442
Nude mice	PDX6 and PDX16 models	Oral	10mg/kg	Once daily for 3 weeks	To evaluate the inhibitory effect of Dacomitinib on ERBB2-mutant tumors, showing tumor growth reduction by 39% and 59% in PDX6 and PDX16, respectively.	Clin Cancer Res. 2019 Jan 15;25(2):641-651

{[proInfo.proName]}

CAS No.: 1110813-31-4

{[proInfo.proName]}

CAS No.: 1110813-31-4

Alternative Products

Product Details of Dacomitinib

Safety of Dacomitinib

Related Pathways of Dacomitinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02097433	Healthy	PHASE1	COMPLETED	2025-09-14	Peking Union Medical College H... More >>ospital, Beijing, 100032, China Less <<
NCT00553254	Carcinoma, Non Small Cell Lung	PHASE2	COMPLETED	2014-07-17	Seoul National University Hosp... More >>ital, Department of Internal Medicine, Seoul, 110-744, Korea, Republic of\|Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, 120-752, Korea, Republic of\|Samsung Medical Center, Department of Medicine, Seoul, 135-710, Korea, Republic of Less <<
NCT04511533	Metastatic Non Small Cell Lung... More >> Cancer Less <<	PHASE4	COMPLETED	2022-11-08	Rajiv Gandhi Cancer Institute ... More >>And Research Centre, New Delhi, Delhi, 110085, India\|The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, 380016, India\|Hemato Oncology Clinic Ahmedabad Pvt. Ltd, Ahmedabad, Gujarat, 380054, India\|Gujarat Hospital - Gastro & Vascular Centre, Surat, Gujarat, 395009, India\|Unity Trauma Center And ICU (Unity Hospital ), Surat, Gujarat, 395009, India\|Artemis hospital, Gurugram, Haryana, 122001, India\|National Cancer Institute, Nagpur, Maharashtra, 441108, India\|Apex Wellness Hospital, Nashik, Maharashtra, 422009, India\|Grant Medical Foundation, Ruby Hall Clinic, Pune, Maharashtra, 411001, India\|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, 411004, India\|Sahyadri Super Speciality Hospital, Pune, Maharashtra, 411004, India\|Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, 401107, India\|Yashoda Hospital, Hyderabad, Telangana State, 500082, India\|Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, WEST Bengal, 700094, India\|Tata Medical Center, Kolkata, WEST Bengal, 700160, India Less <<
NCT01484847	Head and Neck Squamous Cell Ca... More >>rcinoma Less <<		COMPLETED	2025-07-15	Princess Margaret Hospital, To... More >>ronto, Ontario, M5G 2M9, Canada Less <<
NCT01116843	Oral Cavity Cancer	PHASE1\|PHASE2	COMPLETED	2025-02-14	Princess Margaret Hospital, To... More >>ronto, Ontario, M5G 2M9, Canada Less <<
NCT04768491	EGFR Activating Mutation\|NSCLC... More >> Stage IV\|NSCLC Stage IIIB\|NSCLC, Recurrent Less <<		UNKNOWN	2024-10-31	National Cancer Center/Nationa... More >>l Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, 100021, China Less <<
NCT02382796	NSCLC	PHASE2	COMPLETED	2019-05-30	Kanazawa University Hospital, ... More >>Kanazawa City, Ishikawa, 9208641, Japan\|Kurashiki Central Hospital, Kurashiki, Okayama, 710-8602, Japan\|Osaka City General Hospital Department of Clinical Oncology, Osaka-city, Osaka, 534-0021, Japan\|Kindai University Hospital, Osakasayama, Osaka, 589-8511, Japan\|Shizuoka Cancer Center, Suntougun, Shizuoka, 411-8777, Japan\|Cancer Institute Hospital,Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, 135-8550, Japan Less <<
NCT00768664	Head and Neck Neoplasms	PHASE2	COMPLETED	2012-04-18	BC Cancer Agency, Vancouver Ce... More >>ntre, Vancouver, British Columbia, V5Z 4E6, Canada\|Fairmont Medical Building, Vancouver, British Columbia, V5Z1H7, Canada\|Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada\|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada\|London Regional Cancer Centre, London, Ontario, N6A 4L6, Canada\|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada\|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1Y 4K7, Canada\|Sunnybrook Health Sciences Centre: Odette Cancer Center, Toronto, Ontario, M4N 3M5, Canada\|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada\|Hopital Notre-dame du CHUM - Oncology Center, Montreal, Quebec, H2L 4M1, Canada Less <<
NCT00728390	Carcinoma, Non-Small Cell\|Neop... More >>lasm Metastasis Less <<	PHASE1	COMPLETED	2013-01-29	Pfizer Investigational Site, A... More >>mherst, New York, 14221, United States\|Pfizer Investigational Site, Buffalo, New York, 14263, United States\|Pfizer Investigational Site, San Antonio, Texas, 78229, United States\|Pfizer Investigational Site, Villejuif, 94805, France\|Pfizer Investigational Site, Madrid, 28050, Spain Less <<
NCT01728233	Penile Neoplasms\|Carcinoma, Sq... More >>uamous Cell Less <<	PHASE2	COMPLETED	2018-09-21	Fondazione IRCCS Istituto Nazi... More >>onale dei Tumori, Milan, 20133, Italy Less <<
NCT02047747	Brain Cancer	PHASE2	TERMINATED	2025-02-16	UCSD Moores Cancer Center, La ... More >>Jolla, California, 92093-0698, United States Less <<
NCT04339829	Dacomitinib for EGFR Mutated N... More >>on-Small Cell Lung Cancer (NSCLC) With Brain Metastases Less <<	PHASE2	UNKNOWN	2023-08-30	-
NCT00783328	Neoplasms	PHASE1	COMPLETED	2025-03-11	Pfizer Investigational Site, S... More >>unto-gun, Shizuoka, Japan Less <<
NCT04675008	Non Small Cell Lung Cancer\|Bra... More >>in Metastases Less <<	PHASE2	UNKNOWN	2023-03-01	Jong-Mu Sun, Seoul, 06351, Kor... More >>ea, Republic of Less <<
NCT01449201	Head Neck Cancer Squamous Cell... More >> Metastatic\|Head Neck Cancer Squamous Cell Recurrent Less <<	PHASE2	COMPLETED	2025-03-14	Chilgok Kyungpook National Uni... More >>versity Hospital, Daegu, Korea, Republic of\|Dongsan Medical Center, Daegu, Korea, Republic of\|Severance Hospital, Seoul, 120-752, Korea, Republic of\|Asan Medical Center, Seoul, Korea, Republic of\|Samsung Medical Center, Seoul, Korea, Republic of\|Seoul National University Hospital Cancer Center, Seoul, Korea, Republic of Less <<
NCT01112527	Glioblastoma\|GBM\|Glioblastoma ... More >>Multiforme Less <<	PHASE2	COMPLETED	2025-09-15	Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|Henry Ford Hospital, Detroit, Michigan, 48202, United States\|Cleveland Clinic, Cleveland, Ohio, 44195, United States Less <<
NCT00728468	Advanced Malignant Solid Tumor... More >>s Less <<	PHASE1	COMPLETED	2025-07-14	Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States\|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, 78229, United States Less <<
NCT00971191	Non-Small Cell Lung Cancer (NS... More >>CLC) Less <<	PHASE1	TERMINATED	2025-05-12	Pfizer Investigational Site, B... More >>irmingham, Alabama, 35294, United States\|Pfizer Investigational Site, Los Angeles, California, 90048, United States\|Pfizer Investigational Site, Los Angeles, California, 90095, United States Less <<
NCT04609319	Lung Cancer		COMPLETED	2024-05-28	Beijing Cancer Hospital, Beiji... More >>ng, Beijing, 100142, China\|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China\|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China\|Henan Cancer Hospital, Zhengzhou, Henan, 450008, China\|Hunan Provincial Tumor Hospital, Changsha, Hunan, 410013, China\|The First hospital of Jilin University, Changchun, Jilin, 130021, China\|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China\|Internal Medicine, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, 100021, China\|The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China\|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, DEL, 110085, India\|Tata Memorial Center, Kolkata, Kolkata, West Bengal, 700156, India\|Pantai Hospital Kuala Lumpur, Kuala Lumpur, 59100, Malaysia\|University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia\|Beacon Hospital, Petaling Jaya, 46050, Malaysia Less <<
NCT03865446	Severe Hepatic Impairment	PHASE1	COMPLETED	2019-10-24	Investigational Drug Services ... More >>(IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, 33136, United States\|University of Miami Division of Clinical Pharmacology, Miami, Florida, 33136, United States\|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT04027647	NSCLC Stage IIIB\|NSCLC Stage I... More >>IIC\|NSCLC Stage IV\|Recurrent NSCLC\|EGFR Positive Non-Small Cell Lung Cancer Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2026-03-31	Prince of Wales Hospital, Hong... More >> Kong, Hong Kong\|Dong-A University Hospital, Busan, Korea, Republic of\|Seoul National University Hospital, Seoul, Korea, Republic of\|Sarawak General Hospital, Kuching, Sarawak, Malaysia\|University Malaya Medical Centre, Kuala Lumpur, Malaysia\|Beacon Hospital, Petaling Jaya, Malaysia\|National Cancer Centre Singapore, Singapore, Singapore\|Phramongkutklao Hospital, Bangkok, Thailand\|Ramathibodi Hospital, Bangkok, Thailand Less <<
NCT04504071	Non-small Cell Lung Cancer Met... More >>astatic\|EGF-R Positive Non-Small Cell Lung Cancer Less <<	PHASE2	UNKNOWN	2025-12-22	Shanghai Chest hospital, Shang... More >>hai, Shanghai, 200030, China Less <<
NCT00225121	Neoplasms	PHASE1	COMPLETED	2010-09-23	Ronald Reagan UCLA Medical Cen... More >>ter, Los Angeles, California, 90095, United States\|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States\|UCLA Oncology Center, Los Angeles, California, 90095, United States\|UCLA Hematology Oncology - Santa Monica, Santa Monica, California, 90404, United States\|UCLA Santa Monica Hematology/Oncology, Santa Monica, California, 90404, United States\|University of Colorado Hospital, Aurora, Colorado, 80045, United States\|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|Vereniging het Nederlandse Kanker Instituut, Amsterdam, 1066 CX, Netherlands Less <<
NCT02268747	Skin Squamous Cell Cancer	PHASE2	UNKNOWN	2025-11-16	Fondazione IRCCS Istituto Nazi... More >>onale dei Tumori, Milano, Milan, 20133, Italy Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed